Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

enGene Holdings Inc.

35 indications, side-by-side phase, drug & LoA

$1.6

-0.07 (-4.19%)

D 28Pipeline Score Richly Valued Biotech · Clinical
Market Cap
482.32 M
EPS
-2.25
P/E Ratio
-3.19 $
Value Trade
1.38 M
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • R&D Expenses

    22.25 M

  • Operating CF

    -28.90 M

  • Total Assets

    337.11 M

  • Total Liabilities

    55.57 M

  • Equity

    281.55 M

  • D/E Ratio

    12,345

8.11 %
Week
13.23 %
1 Month
47.56 %
3 Month
174.6 %
6 Month
-78.93 %
5 Year
-79.42 %
All Time
Cash Data
Healthy

  • Cash Position

    275.95 M

  • Monthly Burn

    9.63 M

  • Runway

    25.5 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    Mar 9, 2026
Overview
Volume
976.74 K
52 Week Range
2.65 - 12.25
% held by Insiders
58.39 %
% held by Institutions
49.15 %
Enterprise Value
239.77 M
Total Shares
66.99 M
Short %
3.23 %
Float Shares
50.18 M
Company Description
HQ: 4868 RUE LEVY, SUITE 220, SAIN...
Employees:82
https://www.engene.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
BLA Submission example
Detalimogene voraplasmid (detalimogene, previously EG-70) High‑risk, BCG‑unresponsive non‑muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without concomitant papillary disease
BLA
—
-
-
Detalimogene voraplasmid (detalimogene, previously EG-70) High‑risk, BCG‑unresponsive non‑muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without concomitant papillary disease
BLA
—
-
-
Detalimogene voraplasmid (detalimogene, previously EG-70) High‑risk, BCG‑unresponsive non‑muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without concomitant papillary disease
BLA
—
-
-
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
D28
Pipeline Score
$51M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.1x
rNPV / MCap
Top 29%
Micro Cap
(rank 644 of 905)
Percentile Rank
enGene Holdings Inc. faces pipeline headwinds (28/100), with $127M risk-adjusted pipeline value, led by EG-70 in Superficial Bladder Cancer (Phase 2).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
EG-70
Small molecule		Superficial Bladder CancerPhase 2NCT0475272210% $127M RECRUITING 350 STALLED D (26) Nov 1, 2028ELEVATED_RISKLOW
May 24, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
detalimogene voraplasmid
high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS)
Phase 2
2025-06-25
detalimogene voraplasmid
high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS)
Phase 2
2025-06-25
detalimogene voraplasmid
high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS)
Phase 2
2025-06-25
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in ENGN
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
ENGN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ENGN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ENGN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
ENGN Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
ENGN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-06-180 0.00 0 0 - - - - - -
2026-06-180 0.00 0 0 - - - - - -
2026-06-180 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest enGene Holdings Inc. (ENGN) News & Alerts
-
Thursday, June 11, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How ENGN ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Bladder Cancer #28 of 47 N/A EG-70
AZN BMY JNJ
$0.33B 0.8 FOLLOWER